Ibio, Inc. · NASDAQ:IBIO
Ibio — Investor Presentation (August 2021)
32 slides from Ibio's investor presentation, Aug 30, 2021
Slide 1: Growing A Next-Gen Biologics Pipeline
Growing A Next - Gen Biologics Pipeline CORPORATE PRESENTATION: August 2021 Tom Isett, Chairman & CEO
Slide 2: Forward-looking statements
Certain statements in this presentation constitute "forward - looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 , as amended . Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast,
Slide 3: iBio Snapshot
iBio Snapshot Vaccines Therapeutics CDMO Services Research & Bioprocess 3 CDMO Services provide some cash flows + Expanding therapeutic pipeline focused in immuno - oncology and fibrotic diseases + Platform enables rapid vaccine development + Research & Bioprocess products create synergy with other
Slide 4: iBio's Platform Uses Plants for Bioprocessing; Enables Faster, Greener Drug Development
4 iBio’s Platform Uses Plants for Bioprocessing; Enables Faster, Greener Drug Development 130,000 sf FastPharming Facility Sustainability FastPharming Advantages Scalability Speed Safety
Slide 5: iBio's FastPharming System Can Accelerate Drug Development
5 iBio’s FastPharming System Can Accelerate Drug Development Mammalian timelines are for illustrative purposes only based upon competitive data from publicly available sources. Actual t ime lines may vary. Concept to GMP Bulk Drug Substance Acceleration supports earlier safety & stability studies pr
Slide 6: Growing Pipeline
6 Growing Pipeline 1 Received Orphan Drug Designation from U.S. Food & Drug Administration HUMAN HEALTH PROGRAMS PROGRAM INDICATION POC PRE - CLINICAL CLINICAL DEV Classic Swine Fever IBIO - 400 THERAPEUTIC AREA PROGRAM INDICATION DISCOVERY LEAD OPTIMIZATION PRE - CLINICAL IND - ENABLING PHASE I PHA
Slide 7: Therapeutics
Therapeutics Oncology Fibrosis Infectious Diseases
Slide 8: Focusing New Drug Discovery Capabilities on Immuno-Oncology
THERAPEUTICS 8 Focusing New Drug Discovery Capabilities on Immuno - Oncology Speed To Clinic with Enhanced Quality with Glycaneering Technologies TM For Antibody - Dependent Cellular Cytotoxicity (ADCC) Antibody Screening with FairJourney Access to RubrYc’s AI Discovery Platform iBio Oncology Additi
Slide 9: RubrYc Transaction Provides Multiple Potential Sources of Value
THERAPEUTICS 9 RubrYc Transaction Provides Multiple Potential Sources of Value “AI” – Artificial Intelligence Exclusive Global License to RTX - 003, a “second generation” anti - CD25 monoclonal antibody candidate for treatment of solid tumors Equity Stake in RubrYc providing prospective future benef
Slide 10: RTX-003 Stimulates Anti-tumor Immunity via anti-CD25 Treg Depletion
THERAPEUTICS Natural Killer Cell Indiscriminate depletion of T reg + T eff RTX - 003 Stimulates Anti - tumor Immunity via anti - CD25 T reg Depletion 10 T reg = Regulatory T Cells; T eff = Effector T Cells; ADCC = Antibody Dependent Cellular Cytotoxicity T eff JAK JAK 1 st gen anti - CD25 antibodies
Slide 11: RTX-003 Preclinical Data
THERAPEUTICS -2 -1 0 1 2 3 0 500 1000 1500 2000 Tregs Log [Ab], (ng/mL) R L U D11 D11 Afucosylated 11 RTX - 003 Preclinical Data while preserving IL - 2 signaling -3 -2 -1 0 1 0 25 50 75 100 Log [IL-2] (ng/mL) p e r c e n t p s t a t 5 + Dac hD11 wt hD11 Afucosylated Daclizumab RTX - 003 RTX - 003 a
Slide 12: RTX-003 Inhibits Tumor Growth
THERAPEUTICS 12 RTX - 003 Inhibits Tumor Growth RTX - 003 reduced tumor growth in a dose - dependent manner In vivo xenograft mouse model of lymphoma; Administration: 3x / week, i.p.; n=5 per group PBS (Vehicle) 0.3 mg/kg RTX - 003 1.0 mg/kg RTX - 003 3.0 mg/kg RTX - 003 Lymphoma Xenograft Model
Slide 13: RTX-003 in Combination with Checkpoint Inhibitors
THERAPEUTICS 13 RTX - 003 in Combination with Checkpoint Inhibitors RTX - 003 + anti - PD - 1 antibody reduced tumor growth and caused regression in vivo transgenic hCD25 mouse model; RTX - 003 was administered i.p. 3X / week at a single dose (1.5 mg/Kg) in combination with 2 .5 mg/Kg of anti - mous
Slide 14: iBio Gains Access to RubrYc AI-Driven Discovery Platform
THERAPEUTICS 14 iBio Gains Access to RubrYc AI - Driven Discovery Platform • RubrYc uses proprietary predictive algorithms to generate Meso - scale Engineered Molecules (MEMs ) • MEMs are subdominant epitope sequences, transplanted on structural proteins that allow the correct folding of the epitope
Slide 15: Fibrotic & Infectious Diseases
THERAPEUTICS 15 Fibrotic & Infectious Diseases IBIO - 100 for the treatment of fibrotic disorders ACE2 - Fc as a prospective COVID - 19 program
Slide 16: IBIO-100 Promising Therapeutic Candidate for Fibrosis
THERAPEUTICS 16 IBIO - 100 Promising Therapeutic Candidate for Fibrosis *Idiopathic Pulmonary Fibrosis: Disease Landscape & Forecast, Decision Resources, April 6, 2020 IBIO - 100 Collagen Derivative • Involved in ~45% of U.S. deaths from all diseases • No cures: organ transplants for some late - sta
Slide 17: IBIO-100 Demonstrated Compelling Pre-Clinical Proof Of Concept
THERAPEUTICS 17 IBIO - 100 Demonstrated Compelling Pre - Clinical Proof Of Concept Compelling pre - clinical data ▪ Human lung explants : o D emonstrates efficacy in Systemic Scleroderma (SSc ) and Idiopathic Pulmonary Fibrosis (IPF ) diseased human tissue o Note that explant tissue is so far compro
Slide 18: ACE-F2C: Potential COVID Therapeutic
THERAPEUTICS 18 ACE - F2C: Potential COVID - 19 Therapeutic I B IO I N - L ICENSED W ORLDWIDE R IGHTS FOR C ORONAVIRIDAE • ACE2 - Fc is a recombinant protein comprised of human angiotensin converting enzyme 2 (ACE2) fused to a human immunoglobulin G Fc fragment (Fc) • Molecule targets the coronaviru
Slide 19: Vaccines
Vaccines COVID - 19 Classic Swine Fever
Slide 20: IBIO-201 Demonstrated Potential to Raise Antibodies and Prime T-Cells for COVID
VACCINES IBIO - 202 Demonstrated Potential to Raise Antibodies and Prime T - Cells for COVID in Preclinical Studies 20
Slide 21: IBIO-201 Could Be Complementary To Current and Future S-Protein Vaccines
VACCINES 21 IBIO - 202 Could Be Complementary To Current and Future S - Protein Vaccines Adjuvanted to potentially allow for greater immunogenicity and/or dose sparing An “N - only” vaccine may be highly complementary to existing first - generation, S protein – directed vaccines Prospectively suitab
Slide 22: iBio's DAVi Strategy for COVID-19 Vaccines
VACCINES 22 iBio’s “DAVi” Strategy Focuses on Attempting to Solve Multiple Challenges with Current COVID - 19 Vaccines 22 IBIO - 202 Targeting antigens and adjuvants for long lasting protection Exploring alternative routes of administration Seeking protection against a broad spectrum of variants, po
Slide 23: IBIO-400: Classical Swine Fever Vaccine
VACCINES 23 IBIO - 400: Classical Swine Fever Vaccine 1 Richard C. Laughlin et al, 2018. Plant - made E2 glycoprotein single - dose vaccine protects pigs against classical swine fever. Unmet Need iBio’s Approach • iBio is using the FastPharming System to produce an E2 antigen, which may ultimately r
Slide 24: Research & Bioprocess Products and CDMO
Research & Bioprocess Products CDMO
Slide 25: Still Growing CDMO Services while Transforming the Business
CDMO SERVICES 25 Still Growing CDMO Services while Transforming the Business 25 H1 FY21 H1 FY21 $0 $200,000 $400,000 $600,000 $800,000 $1,000,000 $1,200,000 $1,400,000 $1,600,000 $1,800,000 $2,000,000 YTD R EVENUES [= New/Enhanced Offerings Glycaneering TM Development Services Multi - Attribute BioA
Slide 26: New Research and Bioproducts Offerings Launched
26 New Research and Bioproducts Offerings Launched
Slide 27: Summary
Summary
Slide 28: iBio, By the Numbers Summary
iBio, By the Numbers 28 Summary Transformation of plants into high - productivity bioreactors via infiltration complimentary segments with growth opportunities Biopharm pipeline with programs + discovery capability employees (2x v. PY) revenues from relaunched CDMO services Cash reserves of fuels bu
Slide 29: Management Team with Diverse Experience
Experience Tom Isett CEO & Chairman Martin Brenner , DVM, Ph.D. CSO Robert Lutz, MBA CFBO Randy Maddux , MBA COO Lisa Middlebrook CHRO Management Team with Diverse Experience 29
Slide 30: Anticipated Pipeline Milestones
30 Anticipated Pipeline Milestones – Next 12 Months HUMAN HEALTH Program Milestones IBIO - 400 Efficacy Study Results USDA approval - Outline of Production Program Milestones IBIO - 100 IND - enabling study initiation IBIO - 101 IND - enabling study initiation ACE2 - Fc Competitive and regulatory as
Slide 31: Strong and Growing IP Estate Provides Exclusivity for Pipeline
31 Strong and Growing IP Estate Provides Exclusivity for iBio’s Pipeline Issued Patents (30 U.S.) 102 Active Applications (7 U.S.) 19 More Applications progressing to filing Patent Protection includes: • IP for iBio’s pipeline products and vaccines • IP related to the FastPharming Protein Expression
Slide 32: Financial Overview
32 Financial Overview Publicly traded (NYSEA: IBIO) since January 2008 Approximately $103.9 million in cash and cash equivalents plus investments in debt securities as of 31 March 2021 Current cash provides a runway at least through March 2023 Approximately 216.0 million common shares and approximat